Search research articles
Contact Us
Filters
Showing results (111-120 of 173) with videos related to
Page
of 18
Sort By:
Blood Cancer Journal
|
July 30, 2016
First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation
M Wilhelm, M Smetak, P Reimer, et al.
Leukemia & Lymphoma
|
March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma
A Josting, M Reiser, P D Wickramanayake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice
U Kapp, A Düx, E Schell-Frederick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2009
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
J Markova, C Kobe, M Skopalova, et al.
Leukemia & Lymphoma
|
August 26, 1998
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma
R Schnell, E Vitetta, J Schindler, et al.
Cytokines and Molecular Therapy
|
September 1, 1996
A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines
A Klimka, S Barth, S Drillich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting, C Rudolph, M Reiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG
U Rueffer, M Sieber, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF
M Engelhard, H Gerhartz, G Brittinger, et al.
Annals of Hematology
|
May 25, 2002
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia
T Pfitzner, M Reiser, S Barth, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 173) with videos related to
Sort By:
Page
of 18
Blood Cancer Journal
|
July 30, 2016
First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation
M Wilhelm, M Smetak, P Reimer, et al.
Leukemia & Lymphoma
|
March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma
A Josting, M Reiser, P D Wickramanayake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice
U Kapp, A Düx, E Schell-Frederick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2009
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
J Markova, C Kobe, M Skopalova, et al.
Leukemia & Lymphoma
|
August 26, 1998
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma
R Schnell, E Vitetta, J Schindler, et al.
Cytokines and Molecular Therapy
|
September 1, 1996
A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines
A Klimka, S Barth, S Drillich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting, C Rudolph, M Reiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG
U Rueffer, M Sieber, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF
M Engelhard, H Gerhartz, G Brittinger, et al.
Annals of Hematology
|
May 25, 2002
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia
T Pfitzner, M Reiser, S Barth, et al.
Page
of 18